139 results on '"Gandotra S"'
Search Results
2. Implementing a Structured Multidisciplinary Critical Care Curriculum for Critical Care Fellows at a Large Academic Medical Program
- Author
-
Robinson, D., primary, Liu, B., additional, Solomon, G.M., additional, and Gandotra, S., additional
- Published
- 2024
- Full Text
- View/download PDF
3. Effect of sodium–glucose co-transporter-2 inhibitors on survival free of organ support in patients hospitalised for COVID-19 (ACTIV-4a): a pragmatic, multicentre, open-label, randomised, controlled, platform trial
- Author
-
Kosiborod, Mikhail N, Windsor, Sheryl L, Vardeny, Orly, Berger, Jeffrey S, Reynolds, Harmony R, Boumakis, Stavroula, Althouse, Andrew D, Solomon, Scott D, Bhatt, Ankeet S, Peikert, Alexander, Luther, James F, Leifer, Eric S, Kindzelski, Andrei L, Cushman, Mary, Ng Gong, Michelle, Kornblith, Lucy Z, Khatri, Pooja, Kim, Keri S, Baumann Kreuziger, Lisa, Javaheri, Ali, Carpio, Carlos, Wahid, Lana, Lopez-Sendon Moreno, Jose, Alonso, Alvaro, Ho, Minh Quang, Lopez-Sendon, Jose, Lopes, Renato D, Curtis, Jeffrey L, Kirwan, Bridget-Anne, Geraci, Mark W, Neal, Matthew D, Hochman, Judith S, Avancini Caramori, PR, Esteves Hernandes, M, Babudieri, S, Contoli, M, Fernando, M, Gonzalez Juanatey, JR, Ibañez Estellez, F, Mateos, E, Tidswell, M, Akala, O, Pursley, M, Jathavedam, A, Markley, J, Gelman, M, Ajani, Z, Mackay, F, Kunisaki, K, Martin, K, Exline, M, Huggins, J, Nicholson, L, Lim, G, Aboudara, M, Sherwin, R, Torbati, S, Wilson, J, Latorre, JG, Busch, J, Albertson, T, Matthay, M, Gandotra, S, Joseph, B, Hudock, K, Iovine, N, Quigley, J, Hyzy, R, Kutcher, M, Huang, D, Pandey, A, Sheehan, J, Solankhi, N, Huang, D, Rodriguez, W, Shah, B, Khanna, A, Bochicchio, G, McCarthy, M, Pan, S, and Balasubraman, P
- Abstract
Patients hospitalised for COVID-19 are at risk for multiorgan failure and death. Sodium–glucose co-transporter-2 (SGLT2) inhibitors provide cardiovascular and kidney protection in patients with cardiometabolic conditions and could provide organ protection during COVID-19. We aimed to investigate whether SGLT2 inhibitors can reduce the need for organ support in patients hospitalised for COVID-19.
- Published
- 2024
- Full Text
- View/download PDF
4. Laryngoscopy and Tracheal Intubation: Does Use of a Video Laryngoscope Facilitate Both Steps of the Procedure?
- Author
-
Lofrano, A., primary, Prekker, M.E., additional, Trent, S., additional, Russell, D.W., additional, Barnes, C., additional, Brewer, J.M., additional, Doerschug, K.C., additional, Gaillard, J., additional, Gandotra, S., additional, Ginde, A., additional, Ghamande, S., additional, Gibbs, K., additional, Hughes, C.G., additional, Janz, D.R., additional, Khan, A., additional, Mitchell, S., additional, Page, D.B., additional, Rice, T.W., additional, Self, W., additional, Smith, L.M., additional, Stempek, S., additional, Vonderhaar, D.J., additional, West, J.R., additional, Whitson, M.R., additional, Casey, J.D., additional, Semler, M.W., additional, and Driver, B., additional
- Published
- 2023
- Full Text
- View/download PDF
5. Patterns of Vasopressor Delivery and Potential for Reduction in Central Venous Catheter Use
- Author
-
Teja, B., primary, Gandotra, S., additional, Bosch, N.A., additional, Walkey, A.J., additional, and Wunsch, H., additional
- Published
- 2023
- Full Text
- View/download PDF
6. Heterogeneous treatment effects of therapeutic-dose heparin in patients hospitalized for COVID-19
- Author
-
Goligher, EC, Lawler, PR, Jensen, TP, Talisa, V, Berry, LR, Lorenzi, E, McVerry, BJ, Chang, C-CH, Leifer, E, Bradbury, C, Berger, J, Hunt, BJ, Castellucci, LA, Kornblith, LZ, Gordon, AC, McArthur, C, Webb, S, Hochman, J, Neal, MD, Zarychanski, R, Berry, S, Angus, DC, Aday, A, Ahuja, T, Al-Beidh, F, Annane, D, Arabi, YM, Aryal, D, Baumann Kreuziger, L, Beane, A, Berger, JS, Berry, SM, Bhimani, Z, Bihari, S, Billett, HH, Bond, L, Bonten, M, Bradbury, CA, Brooks, MM, Brunkhorst, F, Buxton, M, Buzgau, A, Carrier, M, Castelucci, LA, Chekuri, S, Chen, J-T, Cheng, AC, Chkhikvadze, T, Coiffard, B, Contreras, A, Costantini, TW, Cushman, M, De Brouwer, S, Derde, LPG, Detry, MA, Duggal, A, Džavík, V, Effron, MB, Eng, HF, Escobedo, J, Estcourt, LJ, Everett, BM, Farkough, ME, Fergusson, DA, Fitzgerald, M, Fowler, RA, Froess, JD, Fu, Z, Galanaud, J-P, Galen, BT, Gandotra, S, Girard, TD, Godoy, LD, Gong, MN, Goodman, AL, Goossens, H, Green, C, Greenstein, YY, Gross, PL, Guerrero, RM, Hamburg, N, Haniffa, R, Hanna, G, Hanna, N, Hedge, SM, Hendrickson, CM, Higgins, AM, Hindenburg, AA, Hite, RD, Hochman, JS, Hope, AA, Horowitz, JM, Horvat, CM, Houston, BL, Huang, DT, Hudock, K, Husain, M, Hyzy, RC, Iyer, V, Jacobson, JR, Jayakumar, D, Kahn, SR, Keller, NM, Khan, A, Kim, Y, Kim, KS, Kindzelski, A, King, AJ, Kirwan, B-A, Knudson, MM, Kornblith, AE, Krishnan, V, Kumar, A, Kutcher, ME, Laffan, MA, Lamontagne, F, Le Gal, G, Leeper, CM, Leifer, ES, Lewis, RJ, Lim, G, Lima, FG, Linstrum, K, Litton, E, Lopez-Sendon, J, Lopez-Sendon Moreno, JL, Lother, SA, Madrona, SG, Malhotra, S, Marcos Martin, M, Marshall, JC, Marten, N, Martinez, AS, Martinez, M, Mateos Garcia, E, Matthay, MA, Mavromichalis, S, McArthur, CJ, McAuley, DF, McDonald, EG, McGlothlin, A, McGuinness, SP, McQuilten, ZK, Middeldorp, S, Montgomery, SK, Moore, SC, Mouncey, PR, Murthy, S, Nair, GB, Nair, R, Nichol, AD, Nicolau, JC, Nunez-Garcia, B, Pandey, A, Park, JJ, Park, PK, Parke, RL, Parker, JC, Parnia, S, Paul, JD, Pompilio, M, Prekker, M, Quigley, JG, Reynolds, HR, Rosenson, RS, Rost, NS, Rowan, K, Santos, MO, Santos, FO, Santos, M, Satterwhite, L, Saunders, CT, Schreiber, J, Schutgens, REG, Seymour, CW, Shankar Hari, M, Sheehan, JP, Siegal, DM, Silva Jr., DG, Singhal, AB, Slutsky, AS, Solvason, D, Stanworth, SJ, Tritschler, T, Turgeon, AF, Turner, AM, Van Bentum-Puijk, W, Van de Veerdonk, FL, Van Diepen, S, Vazquez Grande, G, Wahid, L, Wareham, V, Webb, SA, Wells, B, Widmer, RJ, Wilson, JG, Yuriditsky, E, Zampieri, F, and Zhong, Y
- Abstract
Importance Randomized clinical trials (RCTs) of therapeutic-dose heparin in patients hospitalized with COVID-19 produced conflicting results, possibly due to heterogeneity of treatment effect (HTE) across individuals. Better understanding of HTE could facilitate individualized clinical decision-making. Objective To evaluate HTE of therapeutic-dose heparin for patients hospitalized for COVID-19 and to compare approaches to assessing HTE. Design, Setting, and Participants Exploratory analysis of a multiplatform adaptive RCT of therapeutic-dose heparin vs usual care pharmacologic thromboprophylaxis in 3320 patients hospitalized for COVID-19 enrolled in North America, South America, Europe, Asia, and Australia between April 2020 and January 2021. Heterogeneity of treatment effect was assessed 3 ways: using (1) conventional subgroup analyses of baseline characteristics, (2) a multivariable outcome prediction model (risk-based approach), and (3) a multivariable causal forest model (effect-based approach). Analyses primarily used bayesian statistics, consistent with the original trial. Exposures Participants were randomized to therapeutic-dose heparin or usual care pharmacologic thromboprophylaxis. Main Outcomes and Measures Organ support–free days, assigning a value of −1 to those who died in the hospital and the number of days free of cardiovascular or respiratory organ support up to day 21 for those who survived to hospital discharge; and hospital survival. Results Baseline demographic characteristics were similar between patients randomized to therapeutic-dose heparin or usual care (median age, 60 years; 38% female; 32% known non-White race; 45% Hispanic). In the overall multiplatform RCT population, therapeutic-dose heparin was not associated with an increase in organ support–free days (median value for the posterior distribution of the OR, 1.05; 95% credible interval, 0.91-1.22). In conventional subgroup analyses, the effect of therapeutic-dose heparin on organ support–free days differed between patients requiring organ support at baseline or not (median OR, 0.85 vs 1.30; posterior probability of difference in OR, 99.8%), between females and males (median OR, 0.87 vs 1.16; posterior probability of difference in OR, 96.4%), and between patients with lower body mass index (BMI 90% for all comparisons). In risk-based analysis, patients at lowest risk of poor outcome had the highest propensity for benefit from heparin (lowest risk decile: posterior probability of OR >1, 92%) while those at highest risk were most likely to be harmed (highest risk decile: posterior probability of OR
- Published
- 2023
7. An Alabama Cohort of Early 2020 Critically Ill Covid Patients Managed with Supportive Care and Their 90-Day Outcomes
- Author
-
Chiles, J.W., primary, Colon, C.M., additional, Barrios, J.G., additional, Maddox, W.R., additional, Mcdonald, M.-L.N., additional, Kim, Y.-I., additional, Russell, D.W., additional, and Gandotra, S., additional
- Published
- 2022
- Full Text
- View/download PDF
8. Metabolomic Biomarkers Measured at Patient Discharge Predict Long-Term Physical Function in Survivors of Acute Respiratory Failure
- Author
-
Shaw, T., primary, Grant, K., additional, Gandotra, S., additional, Hartsell, E., additional, Daly, G.T., additional, Purcell, L.D., additional, Hamo, M., additional, Gillespie, M.N., additional, Files, D.C., additional, Morris, P.E., additional, and Langley, R.J., additional
- Published
- 2022
- Full Text
- View/download PDF
9. A Case of Functional Internal Decapitation from Rapidly Progressing Ventral Upper Cervical Epidural Abscess
- Author
-
Cheng, C., primary, O'Connor, K., additional, and Gandotra, S., additional
- Published
- 2022
- Full Text
- View/download PDF
10. Effects of Obesity on Respiratory Parameters and Outcomes in a Cohort of Proned COVID-19 ARDS Patients
- Author
-
Goetz, R.L., primary, Chiles, J.W., additional, Gandotra, S., additional, Russell, D., additional, Whitson, M., additional, Dransfield, M.T., additional, and Page, D., additional
- Published
- 2022
- Full Text
- View/download PDF
11. THE MANAGEMENT OF PAIN IN CANCER PATIENTS THROUGH PSYCHOLOGICAL INTERVENTION: WIP16–0384
- Author
-
Gandotra, S.
- Published
- 2016
12. Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19
- Author
-
Goligher, E.C., Bradbury, C.A., McVerry, B.J., Lawler, P.R., Berger, J.S., Gong, M.N., Carrier, M., Reynolds, H.R., Kumar, A., Turgeon, A.F., Kornblith, L.Z., Kahn, S.R., Marshall, J.C., Kim, K.S., Houston, B.L., Derde, L.P.G., Cushman, M., Tritschler, T., Angus, D.C., Godoy, L.C., McQuilten, Z., Kirwan, B.A., Farkouh, M.E., Brooks, M.M., Lewis, R.J., Berry, L.R., Lorenzi, E., Gordon, A.C., Ahuja, T., Al-Beidh, F., Annane, D., Arabi, Y.M., Aryal, D., Kreuziger, L. Baumann, Beane, A., Bhimani, Z., Bihari, S., Billett, H.H., Bond, L., Bonten, M., Brunkhorst, F., Buxton, M., Buzgau, A., Castellucci, L.A., Chekuri, S., Chen, J.T., Cheng, A.C., Chkhikvadze, T., Coiffard, B., Contreras, A., Costantini, T.W., Brouwer, S., Detry, M.A., Duggal, A., Džavík, V., Effron, M.B., Eng, H.F., Escobedo, J., Estcourt, L.J., Everett, B.M., Fergusson, D.A., Fitzgerald, M., Fowler, R.A., Froess, J.D., Fu, Z., Galanaud, J.P., Galen, B.T., Gandotra, S., Girard, T.D., Goodman, A.L., Goossens, H., Green, C., Greenstein, Y.Y., Gross, P.L., Haniffa, R., Hegde, S.M., Hendrickson, C.M., Higgins, A.M., Hindenburg, A.A., Hope, A.A., Horowitz, J.M., Horvat, C.M., Huang, D.T., Hudock, K., Hunt, B.J., Husain, M., Hyzy, R.C., Jacobson, J.R., Jayakumar, D., Keller, N.M., Khan, A., Kim, Y., Kindzelski, A., King, A.J., Knudson, M.M., Kornblith, A.E., Kutcher, M.E., Laffan, M.A., Lamontagne, F., Gal, G. Le, Veerdonk, F.L. van de, Middeldorp, S., Schouten, J.A., Pickkers, P., Webb, S.A., Zarychanski, R., Goligher, E.C., Bradbury, C.A., McVerry, B.J., Lawler, P.R., Berger, J.S., Gong, M.N., Carrier, M., Reynolds, H.R., Kumar, A., Turgeon, A.F., Kornblith, L.Z., Kahn, S.R., Marshall, J.C., Kim, K.S., Houston, B.L., Derde, L.P.G., Cushman, M., Tritschler, T., Angus, D.C., Godoy, L.C., McQuilten, Z., Kirwan, B.A., Farkouh, M.E., Brooks, M.M., Lewis, R.J., Berry, L.R., Lorenzi, E., Gordon, A.C., Ahuja, T., Al-Beidh, F., Annane, D., Arabi, Y.M., Aryal, D., Kreuziger, L. Baumann, Beane, A., Bhimani, Z., Bihari, S., Billett, H.H., Bond, L., Bonten, M., Brunkhorst, F., Buxton, M., Buzgau, A., Castellucci, L.A., Chekuri, S., Chen, J.T., Cheng, A.C., Chkhikvadze, T., Coiffard, B., Contreras, A., Costantini, T.W., Brouwer, S., Detry, M.A., Duggal, A., Džavík, V., Effron, M.B., Eng, H.F., Escobedo, J., Estcourt, L.J., Everett, B.M., Fergusson, D.A., Fitzgerald, M., Fowler, R.A., Froess, J.D., Fu, Z., Galanaud, J.P., Galen, B.T., Gandotra, S., Girard, T.D., Goodman, A.L., Goossens, H., Green, C., Greenstein, Y.Y., Gross, P.L., Haniffa, R., Hegde, S.M., Hendrickson, C.M., Higgins, A.M., Hindenburg, A.A., Hope, A.A., Horowitz, J.M., Horvat, C.M., Huang, D.T., Hudock, K., Hunt, B.J., Husain, M., Hyzy, R.C., Jacobson, J.R., Jayakumar, D., Keller, N.M., Khan, A., Kim, Y., Kindzelski, A., King, A.J., Knudson, M.M., Kornblith, A.E., Kutcher, M.E., Laffan, M.A., Lamontagne, F., Gal, G. Le, Veerdonk, F.L. van de, Middeldorp, S., Schouten, J.A., Pickkers, P., Webb, S.A., and Zarychanski, R.
- Abstract
Item does not contain fulltext, BACKGROUND: Thrombosis and inflammation may contribute to morbidity and mortality among patients with coronavirus disease 2019 (Covid-19). We hypothesized that therapeutic-dose anticoagulation would improve outcomes in critically ill patients with Covid-19. METHODS: In an open-label, adaptive, multiplatform, randomized clinical trial, critically ill patients with severe Covid-19 were randomly assigned to a pragmatically defined regimen of either therapeutic-dose anticoagulation with heparin or pharmacologic thromboprophylaxis in accordance with local usual care. The primary outcome was organ support-free days, evaluated on an ordinal scale that combined in-hospital death (assigned a value of -1) and the number of days free of cardiovascular or respiratory organ support up to day 21 among patients who survived to hospital discharge. RESULTS: The trial was stopped when the prespecified criterion for futility was met for therapeutic-dose anticoagulation. Data on the primary outcome were available for 1098 patients (534 assigned to therapeutic-dose anticoagulation and 564 assigned to usual-care thromboprophylaxis). The median value for organ support-free days was 1 (interquartile range, -1 to 16) among the patients assigned to therapeutic-dose anticoagulation and was 4 (interquartile range, -1 to 16) among the patients assigned to usual-care thromboprophylaxis (adjusted proportional odds ratio, 0.83; 95% credible interval, 0.67 to 1.03; posterior probability of futility [defined as an odds ratio <1.2], 99.9%). The percentage of patients who survived to hospital discharge was similar in the two groups (62.7% and 64.5%, respectively; adjusted odds ratio, 0.84; 95% credible interval, 0.64 to 1.11). Major bleeding occurred in 3.8% of the patients assigned to therapeutic-dose anticoagulation and in 2.3% of those assigned to usual-care pharmacologic thromboprophylaxis. CONCLUSIONS: In critically ill patients with Covid-19, an initial strategy of therapeutic-dose anticoagulati
- Published
- 2021
13. Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19
- Author
-
Lawler, P.R., Goligher, E.C., Berger, J.S., Neal, M.D., McVerry, B.J., Nicolau, J.C., Gong, M.N., Carrier, M., Rosenson, R.S., Reynolds, H.R., Turgeon, A.F., Escobedo, J., Huang, D.T., Bradbury, C.A., Houston, B.L., Kornblith, L.Z., Kumar, A., Kahn, S.R., Cushman, M., McQuilten, Z., Slutsky, A.S., Kim, K.S., Gordon, A.C., Kirwan, B.A., Brooks, M.M., Higgins, A.M., Lewis, R.J., Lorenzi, E., Berry, S.M., Berry, L.R., Aday, A.W., Al-Beidh, F., Annane, D., Arabi, Y.M., Aryal, D., Kreuziger, L. Baumann, Beane, A., Bhimani, Z., Bihari, S., Billett, H.H., Bond, L., Bonten, M., Brunkhorst, F., Buxton, M., Buzgau, A., Castellucci, L.A., Chekuri, S., Chen, J.T., Cheng, A.C., Chkhikvadze, T., Coiffard, B., Costantini, T.W., Brouwer, S., Derde, L.P.G., Detry, M.A., Duggal, A., Džavík, V., Effron, M.B., Estcourt, L.J., Everett, B.M., Fergusson, D.A., Fitzgerald, M., Fowler, R.A., Galanaud, J.P., Galen, B.T., Gandotra, S., García-Madrona, S., Girard, T.D., Godoy, L.C., Goodman, A.L., Goossens, H., Green, C., Greenstein, Y.Y., Gross, P.L., Hamburg, N.M., Haniffa, R., Hanna, G., Hanna, N., Hegde, S.M., Hendrickson, C.M., Hite, R.D., Hindenburg, A.A., Hope, A.A., Horowitz, J.M., Horvat, C.M., Hudock, K., Hunt, B.J., Husain, M., Hyzy, R.C., Iyer, V.N., Jacobson, J.R., Jayakumar, D., Keller, N.M., Khan, A., Kim, Y., Kindzelski, A.L., King, A.J., Knudson, M.M., Kornblith, A.E., Krishnan, V., Veerdonk, F.L. van de, Schouten, J.A., Pickkers, P., Hochman, J.S., Zarychanski, R., Lawler, P.R., Goligher, E.C., Berger, J.S., Neal, M.D., McVerry, B.J., Nicolau, J.C., Gong, M.N., Carrier, M., Rosenson, R.S., Reynolds, H.R., Turgeon, A.F., Escobedo, J., Huang, D.T., Bradbury, C.A., Houston, B.L., Kornblith, L.Z., Kumar, A., Kahn, S.R., Cushman, M., McQuilten, Z., Slutsky, A.S., Kim, K.S., Gordon, A.C., Kirwan, B.A., Brooks, M.M., Higgins, A.M., Lewis, R.J., Lorenzi, E., Berry, S.M., Berry, L.R., Aday, A.W., Al-Beidh, F., Annane, D., Arabi, Y.M., Aryal, D., Kreuziger, L. Baumann, Beane, A., Bhimani, Z., Bihari, S., Billett, H.H., Bond, L., Bonten, M., Brunkhorst, F., Buxton, M., Buzgau, A., Castellucci, L.A., Chekuri, S., Chen, J.T., Cheng, A.C., Chkhikvadze, T., Coiffard, B., Costantini, T.W., Brouwer, S., Derde, L.P.G., Detry, M.A., Duggal, A., Džavík, V., Effron, M.B., Estcourt, L.J., Everett, B.M., Fergusson, D.A., Fitzgerald, M., Fowler, R.A., Galanaud, J.P., Galen, B.T., Gandotra, S., García-Madrona, S., Girard, T.D., Godoy, L.C., Goodman, A.L., Goossens, H., Green, C., Greenstein, Y.Y., Gross, P.L., Hamburg, N.M., Haniffa, R., Hanna, G., Hanna, N., Hegde, S.M., Hendrickson, C.M., Hite, R.D., Hindenburg, A.A., Hope, A.A., Horowitz, J.M., Horvat, C.M., Hudock, K., Hunt, B.J., Husain, M., Hyzy, R.C., Iyer, V.N., Jacobson, J.R., Jayakumar, D., Keller, N.M., Khan, A., Kim, Y., Kindzelski, A.L., King, A.J., Knudson, M.M., Kornblith, A.E., Krishnan, V., Veerdonk, F.L. van de, Schouten, J.A., Pickkers, P., Hochman, J.S., and Zarychanski, R.
- Abstract
Item does not contain fulltext, BACKGROUND: Thrombosis and inflammation may contribute to the risk of death and complications among patients with coronavirus disease 2019 (Covid-19). We hypothesized that therapeutic-dose anticoagulation may improve outcomes in noncritically ill patients who are hospitalized with Covid-19. METHODS: In this open-label, adaptive, multiplatform, controlled trial, we randomly assigned patients who were hospitalized with Covid-19 and who were not critically ill (which was defined as an absence of critical care-level organ support at enrollment) to receive pragmatically defined regimens of either therapeutic-dose anticoagulation with heparin or usual-care pharmacologic thromboprophylaxis. The primary outcome was organ support-free days, evaluated on an ordinal scale that combined in-hospital death (assigned a value of -1) and the number of days free of cardiovascular or respiratory organ support up to day 21 among patients who survived to hospital discharge. This outcome was evaluated with the use of a Bayesian statistical model for all patients and according to the baseline d-dimer level. RESULTS: The trial was stopped when prespecified criteria for the superiority of therapeutic-dose anticoagulation were met. Among 2219 patients in the final analysis, the probability that therapeutic-dose anticoagulation increased organ support-free days as compared with usual-care thromboprophylaxis was 98.6% (adjusted odds ratio, 1.27; 95% credible interval, 1.03 to 1.58). The adjusted absolute between-group difference in survival until hospital discharge without organ support favoring therapeutic-dose anticoagulation was 4.0 percentage points (95% credible interval, 0.5 to 7.2). The final probability of the superiority of therapeutic-dose anticoagulation over usual-care thromboprophylaxis was 97.3% in the high d-dimer cohort, 92.9% in the low d-dimer cohort, and 97.3% in the unknown d-dimer cohort. Major bleeding occurred in 1.9% of the patients receiving therapeutic-dose anticoagul
- Published
- 2021
14. Supplement to: Perilipin deficiency and autosomal dominant partial lipodystrophy.
- Author
-
Gandotra, S, Le Dour, C, and Bottomley, W
- Published
- 2011
15. Covid Convalescence Interrupted
- Author
-
Chiles, J.W., primary, Gandotra, S., additional, and Russell, D., additional
- Published
- 2021
- Full Text
- View/download PDF
16. Functional endoscopic sinus surgery results in 69 patients
- Author
-
Chaudhary, Neena, Kapoor, Rajeev, Motwani, Gul, and Gandotra, S. C.
- Published
- 1999
- Full Text
- View/download PDF
17. Role of computed tomography in unsafe chronic suppurative otitis media
- Author
-
Berry, Sandeep, Gandotra, S. C., and Saxena, N. C.
- Published
- 1998
- Full Text
- View/download PDF
18. Granulocyte colony-stimulating factor dosing in pegylated interferon alpha-induced neutropenia and its impact on outcome of anti-HCV therapy
- Author
-
Koirala, J., Gandotra, S. D., Rao, S., Sangwan, G., Mushtaq, A., Htwe, T. H., Adamski, A., Blessman, D., and Khardori, N. M.
- Published
- 2007
19. Tuberculosis of tongue
- Author
-
Mehta, Jyoti, Chaudhary, Neena, Mittal, Atul, Motwani, Gul, and Gandotra, S. C.
- Published
- 1998
- Full Text
- View/download PDF
20. Antrochoanal polyp-a cause of obstructive sleep apnoea in children
- Author
-
Venkatachalam, V. P., Gupta, Neelima, Suri, J. C., and Gandotra, S. C.
- Published
- 1998
- Full Text
- View/download PDF
21. Understanding the Social in Social Media: An Analysis of Tweeting Behaviors of Pulmonary and Critical Care Fellowship Programs
- Author
-
Gandotra, S., primary, Stewart, N.H., additional, Khateeb, D., additional, Garcha, P.S., additional, Carlos, W.G., additional, Carroll, C.L., additional, and Kaul, V., additional
- Published
- 2019
- Full Text
- View/download PDF
22. The Presence of Pulmonary and Critical Care Programs on Social Media
- Author
-
Kaul, V., primary, Stewart, N.H., additional, Khateeb, D., additional, Garcha, P.S., additional, Carlos, W.G., additional, Carroll, C.L., additional, and Gandotra, S., additional
- Published
- 2019
- Full Text
- View/download PDF
23. Bacterial community structure and diversity in the gut of the muga silkworm,Antheraea assamensis(Lepidoptera: Saturniidae), from India
- Author
-
Gandotra, S., primary, Kumar, A., additional, Naga, K., additional, Bhuyan, P. M., additional, Gogoi, D. K., additional, Sharma, K., additional, and Subramanian, S., additional
- Published
- 2018
- Full Text
- View/download PDF
24. Extractive Approaches for Automatic Text Summarization
- Author
-
Gandotra, S., primary and Arora, B., additional
- Published
- 2018
- Full Text
- View/download PDF
25. Management of cesarean section in a patient with paraplegia and difficult airway with full stomach
- Author
-
Gandotra S
- Subjects
0301 basic medicine ,medicine.medical_specialty ,business.industry ,Stomach ,Section (typography) ,04 agricultural and veterinary sciences ,medicine.disease ,Surgery ,03 medical and health sciences ,030104 developmental biology ,medicine.anatomical_structure ,040102 fisheries ,0401 agriculture, forestry, and fisheries ,Medicine ,business ,Paraplegia ,Difficult airway - Published
- 2017
- Full Text
- View/download PDF
26. Bacterial community structure and diversity in the gut of the muga silkworm, Antheraea assamensis (Lepidoptera: Saturniidae), from India.
- Author
-
Gandotra, S., Kumar, A., Naga, K., Bhuyan, P. M., Gogoi, D. K., Sharma, K., and Subramanian, S.
- Subjects
- *
MUGA moth , *GUT microbiome , *RIBOSOMAL RNA , *INSECT phylogeny , *BACTERIAL cultures - Abstract
Abstract: The muga silkworm, Antheraea assamensis, is exclusively present in the northeastern regions of India and rearing of this silkworm is a vocation unique to this region in the world. Through culture‐dependent techniques, generic identification using 16S ribosomal RNA probes, diversity analysis and qualitative screening for enzyme activities, our studies have identified a number of bacterial isolates, viz. Bacillus spp., Serratia marcescens, Stenotrophomonas maltophilia, Pseudomonas stutzeri, Acinetobacter sp. and Alcaligens sp., inhabiting the gut of the muga silkworm. Analysis of the culturable bacterial community from the gut of An. assamensis revealed that Bacillus (54%) was the predominant bacterial genus followed by Serratia (24%), Pseudomonas (10%) and Alcaligens (6%). Significant differences in the Shannon–Wiener (H') and Simpson (D) diversity indices of gut bacteria were recorded for An. assamensis collected from different regions. H' and D values were found to be highest for An. assamensis from the Titabar region (H' = 4.73 ± 0.43; D = 10.00 ± 0.11) and lowest for individuals from the Mendipathar region (H' = 2.1 ± 0.05; D = 0.04 ± 0.00) of northeastern India. Qualitative screening for enzyme activities identified about 26 gut bacterial isolates having significantly higher cellulose, amylase and lipase activities. These isolates probably contribute to the digestion and nutrition of their host insect, An. assamensis. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
27. Antidepressants, anxiolytics, and hypnotics in pregnancy and lactation
- Author
-
Gandotra, S, primary and Ram, Daya, additional
- Published
- 2015
- Full Text
- View/download PDF
28. 011 Des mutations inactivatrices de la périlipine sont responsables d’un syndrome lipodystrophique de transmission autosomique dominante chez l’homme
- Author
-
Le Dour, C., primary, Gandotra, S., additional, Bottomley, W., additional, Cervera, P., additional, Giral, P., additional, Reznik, Y., additional, Charpentier, G., additional, Auclair, M., additional, Lascols, O., additional, Capeau, J., additional, O’Rahilly, S., additional, Savage, D., additional, and Vigouroux, C., additional
- Published
- 2011
- Full Text
- View/download PDF
29. Antidepressants, anxiolytics, and hypnotics in pregnancy and lactation.
- Author
-
Ram, Daya and Gandotra, S.
- Subjects
- *
MENTAL illness drug therapy , *DRUG-induced abnormalities , *ANTIDEPRESSANTS , *ANTIPSYCHOTIC agents , *BENZODIAZEPINES , *DOSE-effect relationship in pharmacology , *LACTATION , *EVALUATION of medical care , *MEDLINE , *MONOAMINE oxidase inhibitors , *ONLINE information services , *PREGNANCY , *PSYCHIATRIC drugs , *PUERPERIUM , *SEROTONIN uptake inhibitors , *TERATOGENIC agents , *TRANQUILIZING drugs , *SYSTEMATIC reviews , *DISEASE risk factors - Abstract
Aims: Untreated perinatal depression and anxiety disorders are known to have significant negative impact on both maternal and fetal health. Dilemmas still remain regarding the use and safety of psychotropics in pregnant and lactating women suffering from perinatal depression and anxiety disorders. The aim of the current paper was to review the existing evidence base on the exposure and consequences of antidepressants, anxiolytics, and hypnotics in women during pregnancy and lactation and to make recommendations for clinical decision making in management of these cases. Materials and Methods: We undertook a bibliographic search of Medline/PubMed (1972 through 2014), Science Direct (1972 through 2014), Archives of Indian Journal of Psychiatry databases was done. References of retrieved articles, reference books, and dedicated websites were also checked. Results and Conclusions: The existing evidence base is extensive in studying multiple outcomes of the antidepressant or anxiolytic exposure in neonates, and some of the findings appear conflicting. Selective serotonin reuptake inhibitors are the most researched antidepressants in pregnancy and lactation. The available literature is criticized mostly on the lack of rigorous well designed controlled studies as well as lacunae in the methodologies, interpretation of statistical information, knowledge transfer, and translation of information. Research in this area in the Indian context is strikingly scarce. Appropriate risk‑benefit analysis of untreated mental illness versus medication exposure, tailor‑made to each patient's past response and preference within in the context of the available evidence should guide clinical decision making. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
30. Functional endoscopic sinus surgery results in 69 patients.
- Author
-
Chaudhary, Neena, Kapoor, Rajeev, Motwani, Gul, and Gandotra, S.
- Abstract
Sixty nine patients with sinonasal symptoms were subjected to diagnostic endoscopy. Functional endoscopic sinus surgery was done subsequently for chronic sinusitis in 42 patients, for ethmoidal polypi in 18 patients and for antrochoanal polypi in 9 patients. A follow up of 18 to 36 months ( mean 27 months) reveals a success rate of 84% in the overall study, 81.5% in patients with chronic sinusitis alone, 87.5% in ethmoidal polypi and 100% in patients with antrochoanal polyps. [ABSTRACT FROM AUTHOR]
- Published
- 2000
- Full Text
- View/download PDF
31. Global workspace model of consciousness and its electromagnetic correlates
- Author
-
Prakash Ravi, Prakash Om, Prakash Shashi, Abhishek Priyadarshi, and Gandotra Sachin
- Subjects
Electromagnetic field ,global workspace ,Neurology. Diseases of the nervous system ,RC346-429 - Abstract
The global workspace of consciousness was proposed in its elementary framework by Baars, in 1982. Since the time of inception, there have been many speculations and modifications of this theory, but the central theme has remained the same, which refers to the global availability of information in the brain. However, the present understanding about the origin of this global workspace or its mechanism of operation is still deficient. One of the less-studied candidates for this global workspace is the electromagnetic field of the brain. The present work is a brief review of the theoretical underpinnings of the Global workspace model, in terms of its theoretical framework and neuroimaging evidences. Subsequently, we turn towards another broad group of theories of consciousness, in the form of electromagnetic field theories. We then proceed to highlight some electromagnetic correlates derived from these theories for this global access phenomenon.
- Published
- 2008
32. Noninvasive Ventilation for Preoxygenation during Emergency Intubation.
- Author
-
Gibbs, K. W., Semler, M. W., Driver, B. E., Seitz, K. P., Stempek, S. B., Taylor, C., Resnick-Ault, D., White, H. D., Gandotra, S., Doerschug, K. C., Mohamed, A., Prekker, M. E., Khan, A., Gaillard, J. P., Andrea, L., Aggarwal, N. R., Brainard, J. C., Barnett, L. A. H., Halliday, S. J., and Blinder, V.
- Subjects
- *
NONINVASIVE ventilation , *OXYGEN saturation , *INTUBATION , *TRACHEA intubation , *OXYGEN masks - Abstract
BACKGROUND Among critically ill adults undergoing tracheal intubation, hypoxemia increases the risk of cardiac arrest and death. The effect of preoxygenation with noninvasive ventilation, as compared with preoxygenation with an oxygen mask, on the incidence of hypoxemia during tracheal intubation is uncertain. METHODS In a multicenter, randomized trial conducted at 24 emergency departments and intensive care units in the United States, we randomly assigned critically ill adults (age, ≥18 years) undergoing tracheal intubation to receive preoxygenation with either noninvasive ventilation or an oxygen mask. The primary outcome was hypoxemia during intubation, defined by an oxygen saturation of less than 85% during the interval between induction of anesthesia and 2 minutes after tracheal intubation. RESULTS Among the 1301 patients enrolled, hypoxemia occurred in 57 of 624 patients (9.1%) in the noninvasive-ventilation group and in 118 of 637 patients (18.5%) in the oxygen-mask group (difference, -9.4 percentage points; 95% confidence interval [CI], -13.2 to -5.6; P<0.001). Cardiac arrest occurred in 1 patient (0.2%) in the noninvasive-ventilation group and in 7 patients (1.1%) in the oxygen-mask group (difference, -0.9 percentage points; 95% CI, -1.8 to -0.1). Aspiration occurred in 6 patients (0.9%) in the noninvasive-ventilation group and in 9 patients (1.4%) in the oxygen-mask group (difference, -0.4 percentage points; 95% CI, -1.6 to 0.7). CONCLUSIONS Among critically ill adults undergoing tracheal intubation, preoxygenation with noninvasive ventilation resulted in a lower incidence of hypoxemia during intubation than preoxygenation with an oxygen mask. (Funded by the U.S. Department of Defense; PREOXI ClinicalTrials.gov number, NCT05267652.) [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
33. Investigate The Effect of Additives on Mechanical Properties During Casting of 6351 Aluminium
- Author
-
Kumar Sanjeev, Gandotra Sandeep, Kumar Sunil, Nripjit, and Tripathi Himanshu
- Subjects
Coal dust ,Tamarind Powder ,Starch Powder ,Tensile Strength ,Hardness ,Engineering (General). Civil engineering (General) ,TA1-2040 - Abstract
Aluminum is one of the significant and widely used metals in the manufacturing industries. The effectiveness of casting processes depends upon various process parameters like type of sand, moulding process and additive used. However, the additive in the sand plays important roles to make a perfect casting. Hence, in this research work the experiment were performed to investigate the effect of additives like Tamarind Powder, Starch Powder and Coal dust on the Mechanical Properties namely during casting of aluminium alloys.
- Published
- 2016
- Full Text
- View/download PDF
34. Video versus Direct Laryngoscopy for Tracheal Intubation of Critically Ill Adults.
- Author
-
Prekker, M. E., Driver, B. E., Trent, S. A., Resnick-Ault, D., Seitz, K. P., Russell, D. W., Gaillard, J. P., Latimer, A. J., Ghamande, S. A., Gibbs, K. W., Vonderhaar, D. J., Whitson, M. R., Barnes, C. R., Walco, J. P., Douglas, I. S., Krishnamoorthy, V., Dagan, A., Bastman, J. J., Lloyd, B. D., and Gandotra, S.
- Subjects
- *
LARYNGOSCOPY , *TRACHEA intubation , *CRITICALLY ill , *CRITICAL care medicine , *VIDEO production & direction , *ADULTS - Abstract
BACKGROUND Whether video laryngoscopy as compared with direct laryngoscopy increases the likelihood of successful tracheal intubation on the first attempt among critically ill adults is uncertain. METHODS In a multicenter, randomized trial conducted at 17 emergency departments and intensive care units (ICUs), we randomly assigned critically ill adults undergoing tracheal intubation to the video-laryngoscope group or the direct-laryngoscope group. The primary outcome was successful intubation on the first attempt. The secondary outcome was the occurrence of severe complications during intubation; severe complications were defined as severe hypoxemia, severe hypotension, new or increased vasopressor use, cardiac arrest, or death. RESULTS The trial was stopped for efficacy at the time of the single preplanned interim analysis. Among 1417 patients who were included in the final analysis (91.5% of whom underwent intubation that was performed by an emergency medicine resident or a critical care fellow), successful intubation on the first attempt occurred in 600 of the 705 patients (85.1%) in the video-laryngoscope group and in 504 of the 712 patients (70.8%) in the direct-laryngoscope group (absolute risk difference, 14.3 percentage points; 95% confidence interval [CI], 9.9 to 18.7; PcO.OOl). A total of 151 patients (21.4%) in the video-laryngoscope group and 149 patients (20.9%) in the direct-laryngoscope group had a severe complication during intubation (absolute risk difference, 0.5 percentage points; 95% CI, -3.9 to 4.9). Safety outcomes, including esophageal intubation, injury to the teeth, and aspiration, were similar in the two groups. CONCLUSIONS Among critically ill adults undergoing tracheal intubation in an emergency department or ICU, the use of a video laryngoscope resulted in a higher incidence of successful intubation on the first attempt than the use of a direct laryngoscope. (Funded by the U.S. Department of Defense; DEVICE ClinicalTrials.gov number, NCT05239195). [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
35. Amisulpride improved debilitating clozapine-induced sialorrhea.
- Author
-
Praharaj SK, Ray P, and Gandotra S
- Published
- 2011
- Full Text
- View/download PDF
36. Cytometry masked autoencoder: An accurate and interpretable automated immunophenotyper.
- Author
-
Kim J, Ionita M, Lee M, McKeague ML, Pattekar A, Painter MM, Wagenaar J, Truong V, Norton DT, Mathew D, Nam Y, Apostolidis SA, Clendenin C, Orzechowski P, Jung SH, Woerner J, Ittner CAG, Turner AP, Esperanza M, Dunn TG, Mangalmurti NS, Reilly JP, Meyer NJ, Calfee CS, Liu KD, Matthy MA, Swigart LB, Burnham EL, McKeehan J, Gandotra S, Russel DW, Gibbs KW, Thomas KW, Barot H, Greenplate AR, Wherry EJ, and Kim D
- Subjects
- Humans, Single-Cell Analysis methods, Algorithms, Immunophenotyping methods, Flow Cytometry methods
- Abstract
Single-cell cytometry data are crucial for understanding the role of the immune system in diseases and responses to treatment. However, traditional methods for annotating cytometry data face challenges in scalability, robustness, and accuracy. We propose a cytometry masked autoencoder (cyMAE), which automates immunophenotyping tasks including cell type annotation. The model upholds user-defined cell type definitions, facilitating interpretability and cross-study comparisons. The training of cyMAE has a self-supervised phase, which leverages large amounts of unlabeled data, followed by fine-tuning on specialized tasks using smaller amounts of annotated data. The cost of training a new model is amortized over repeated inferences on new datasets using the same panel. Through validation across multiple studies using the same panel, we demonstrate that cyMAE delivers accurate and interpretable cellular immunophenotyping and improves the prediction of subject-level metadata. This proof of concept marks a significant step forward for large-scale immunology studies., Competing Interests: Declaration of interests E.J.W. is a member of the Parker Institute for Cancer Immunotherapy, which supports cancer immunotherapy research in his laboratory. E.J.W. is an advisor for Arsenal Biosciences, Coherus, Danger Bio, IpiNovyx, NewLimit, Marengo, Pluto Immunotherapeutics, Related Sciences, Santa Ana Bio, and Synthekine. E.J.W. is a founder of and holds stock in Coherus, Danger Bio, Prox Biosciences, and Arsenal Biosciences., (Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
37. Association Between Neuromuscular Blocking Agents and Outcomes of Emergency Tracheal Intubation: A Secondary Analysis of Randomized Trials.
- Author
-
DeMasi SC, Self WH, Aggarawal NR, April MD, Andrea L, Barnes CR, Brainard J, Blinder V, Dagan A, Driver B, Doerschug KC, Douglas I, Exline M, Fein DG, Gaillard JP, Gandotra S, Gibbs KW, Ginde AA, Halliday SJ, Han JH, Herbert T, High K, Hughes CG, Khan A, Latimer AJ, Maiga AW, Mitchell SH, Muhs AL, Mohamed A, Moskowitz A, Page DB, Palakshappa JA, Prekker ME, Qian ET, Resnick-Ault D, Rice TW, Russel DW, Schauer SG, Seitz KP, Shapiro NI, Smith LM, Sottile P, Stempek S, Trent SA, Vonderhaar DJ, Walker JE, Wang L, Whitson MR, Casey JD, and Semler MW
- Abstract
Study Objective: To examine the association between the neuromuscular blocking agent received (succinylcholine versus rocuronium) and the incidences of successful intubation on the first attempt and severe complications during tracheal intubation of critically ill adults in an emergency department (ED) or ICU., Methods: We performed a secondary analysis of data from 2 multicenter randomized trials in critically ill adults undergoing tracheal intubation in an ED or ICU. Using a generalized linear mixed-effects model with prespecified baseline covariates, we examined the association between the neuromuscular blocking agent received (succinylcholine versus rocuronium) and the incidences of successful intubation on the first attempt (primary outcome) and severe complications during tracheal intubation (secondary outcome)., Results: Among the 2,440 patients in the trial data sets, 2,339 (95.9%) were included in the current analysis; 475 patients (20.3%) received succinylcholine and 1,864 patients (79.7%) received rocuronium. Successful intubation on the first attempt occurred in 375 patients (78.9%) who received succinylcholine and 1,510 patients (81.0%) who received rocuronium (an adjusted odds ratio of 0.87; 95% CI 0.65 to 1.15). Severe complications occurred in 67 patients (14.1%) who received succinylcholine and 456 patients (24.5%) who received rocuronium (adjusted odds ratio, 0.88; 95% CI 0.62 to 1.26)., Conclusion: Among critically ill adults undergoing tracheal intubation, the incidences of successful intubation on the first attempt and severe complications were not significantly different between patients who received succinylcholine and patients who received rocuronium., (Copyright © 2024 American College of Emergency Physicians. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
38. POINT: Direct Laryngoscopy: The Building Block to Airway Expertise? Yes.
- Author
-
Resnick-Ault D, Gandotra S, and Gaillard JP
- Subjects
- Humans, Airway Management methods, Intubation, Intratracheal methods, Laryngoscopy methods, Clinical Competence
- Abstract
Competing Interests: Financial/Nonfinancial Disclosures None declared.
- Published
- 2024
- Full Text
- View/download PDF
39. Rebuttal From Drs Resnick-Ault, Gandotra, and Gaillard.
- Author
-
Resnick-Ault D, Gandotra S, and Gaillard JP
- Abstract
Competing Interests: Financial/Nonfinancial Disclosures None declared.
- Published
- 2024
- Full Text
- View/download PDF
40. Psychological Distress After Inpatient Noncardiac Surgery: A Secondary Analysis of the Measurement of Exercise Tolerance Before Surgery Prospective Cohort Study.
- Author
-
Gandotra S, Daza JF, Diep C, Mitani AA, Ladha KS, and Wijeysundera DN
- Subjects
- Adult, Male, Middle Aged, Female, Humans, Cohort Studies, Prospective Studies, Exercise Tolerance, Stress, Psychological epidemiology, Stress, Psychological etiology, Stress, Psychological psychology, Inpatients, Psychological Distress
- Abstract
Objective: To describe the incidence and natural progression of psychological distress after major surgery., Background: The recovery process after surgery imposes physical and mental burdens that put patients at risk of psychological distress. Understanding the natural course of psychological distress after surgery is critical to supporting the timely and tailored management of high-risk individuals., Methods: We conducted a secondary analysis of the "Measurement of Exercise Tolerance before Surgery" multicentre cohort study (Canada, Australia, New Zealand, and the UK). Measurement of Exercise Tolerance before Surgery recruited adult participants (≥40 years) undergoing elective inpatient noncardiac surgery and followed them for 1 year. The primary outcome was the severity of psychological distress measured using the anxiety-depression item of EQ-5D-3L. We used cumulative link mixed models to characterize the time trajectory of psychological distress among relevant patient subgroups. We also explored potential predictors of severe and/or worsened psychological distress at 1 year using multivariable logistic regression models., Results: Of 1546 participants, moderate-to-severe psychological distress was reported by 32.6% of participants before surgery, 27.3% at 30 days after surgery, and 26.2% at 1 year after surgery. Psychological distress appeared to improve over time among females [odds ratio (OR): 0.80, 95% CI: 0.65-0.95] and patients undergoing orthopedic procedures (OR: 0.73, 95% CI: 0.55-0.91), but not among males (OR: 0.87, 95% CI: 0.87-1.07) or patients undergoing nonorthopedic procedures (OR: 0.95, 95% CI: 0.87-1.04). Among the average middle-aged adult, there were no time-related changes (OR: 0.94, 97% CI: 0.75-1.13), whereas the young-old (OR: 0.89, 95% CI: 0.79-0.99) and middle-old (OR: 0.87, 95% CI: 0.73-1.01) had small improvements. Predictors of severe and/or worsened psychological distress at 1 year were younger age, poor self-reported functional capacity, smoking history, and undergoing open surgery., Conclusions: One-third of adults experience moderate to severe psychological distress before major elective noncardiac surgery. This distress tends to persist or worsen over time among select patient subgroups., Competing Interests: J.F.D. is supported by a Vanier Graduate Scholarship and a research scholarship from the Division of General Surgery at the University of Toronto. C.D. is supported in part by an Ontario Graduate Scholarship. K.S.L. is supported by a Merit Award from the Department of Anesthesiology and Pain Medicine at the University of Toronto. D.N.W. is supported in part by a Merit Award from the Department of Anesthesiology and Pain Medicine at the University of Toronto and the Endowed Chair in Translational Anesthesiology Research at St. Michael’s Hospital and the University of Toronto. The remaining authors report no conflicts of interest., (Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
41. Field based research in the era of the pandemic in resource limited settings: challenges and lessons for the future.
- Author
-
Mulchandani R, Lyngdoh T, Gandotra S, Isser HS, Dhamija RK, and Kakkar AK
- Subjects
- Humans, Pandemics prevention & control, Communication, Developing Countries, COVID-19 epidemiology, Health Literacy
- Abstract
The coronavirus pandemic that began in December 2019, has had an unprecedented impact on the global economy, health systems and infrastructure, in addition to being responsible for significant mortality and morbidity worldwide. The "new normal" has brought along, unforeseen challenges for the scientific community, owing to obstructions in conducting field-based research in lieu of minimizing exposure through in-person contact. This has had greater ramifications for the LMICs, adding to the already existing concerns. As a response to COVID-19 related movement restrictions, public health researchers across countries had to switch to remote data collections methods. However, impediments like lack of awareness and skepticism among participants, dependence on paper-based prescriptions, dearth of digitized patient records, gaps in connectivity, reliance on smart phones, concerns with participant privacy at home and greater loss to follow-up act as hurdles to carrying out a research study virtually, especially in resource-limited settings. Promoting health literacy through science communication, ensuring digitization of health records in hospitals, and employing measures to encourage research participation among the general public are some steps to tackle barriers to remote research in the long term. COVID-19 may not be a health emergency anymore, but we are not immune to future pandemics. A more holistic approach to research by turning obstacles into opportunities will not just ensure a more comprehensive public health response in the coming time, but also bolster the existing infrastructure for a stronger healthcare system for countries., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision., (Copyright © 2024 Mulchandani, Lyngdoh, Gandotra, Isser, Dhamija and Kakkar.)
- Published
- 2024
- Full Text
- View/download PDF
42. Use of inhaled nitric oxide to manage hypoxia during one-lung ventilation: A case study.
- Author
-
Gandotra S and Darrah WC
- Abstract
Competing Interests: There are no conflicts of interest.
- Published
- 2023
- Full Text
- View/download PDF
43. ARL8B mediates lipid droplet contact and delivery to lysosomes for lipid remobilization.
- Author
-
Menon D, Bhapkar A, Manchandia B, Charak G, Rathore S, Jha RM, Nahak A, Mondal M, Omrane M, Bhaskar AK, Thukral L, Thiam AR, and Gandotra S
- Subjects
- Humans, Signal Transduction, Lysosomes metabolism, Lipids, Lipid Metabolism, ADP-Ribosylation Factors metabolism, Lipid Droplets metabolism, Monomeric GTP-Binding Proteins metabolism
- Abstract
Lipid droplets (LDs) play a crucial role in maintaining cellular lipid balance by storing and delivering lipids as needed. However, the intricate lipolytic pathways involved in LD turnover remain poorly described, hindering our comprehension of lipid catabolism and related disorders. Here, we show a function of the small GTPase ARL8B in mediating LD turnover in lysosomes. ARL8B-GDP localizes to LDs, while ARL8-GTP predominantly favors lysosomes. GDP binding induces a conformation with an exposed N-terminal amphipathic helix, enabling ARL8B to bind to LDs. By associating with LDs and lysosomes, and with its property to form a heterotypic complex, ARL8B mediates LD-lysosome contacts and efficient lipid transfer between these organelles. In human macrophages, this ARL8B-dependent LD turnover mechanism appears as the major lipolytic pathway. Our finding opens exciting possibilities for understanding the molecular mechanisms underlying LD degradation and its potential implications for inflammatory disorders., Competing Interests: Declaration of interests The authors declare no competing interests., (Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
44. Laryngoscopy and Tracheal Intubation: Does Use of a Video Laryngoscope Facilitate Both Steps of the Procedure?
- Author
-
Prekker ME, Trent SA, Lofrano A, Russell DW, Barnes CR, Brewer JM, Doerschug KC, Gaillard JP, Gandotra S, Ginde AA, Ghamande S, Gibbs KW, Hughes CG, Janz DR, Khan A, Mitchell SH, Page DB, Rice TW, Self WH, Smith LM, Stempek SB, Vonderhaar DJ, West JR, Whitson MR, Casey JD, Semler MW, and Driver BE
- Subjects
- Adult, Humans, Critical Illness, Intubation, Intratracheal methods, Trachea, Video Recording, Laryngoscopy methods, Laryngoscopes
- Abstract
Study Objective: To compare the effect of the use of a video laryngoscope versus a direct laryngoscope on each step of emergency intubation: laryngoscopy (step 1) and intubation of the trachea (step 2)., Methods: In a secondary observational analysis of data from 2 multicenter, randomized trials that enrolled critically ill adults undergoing tracheal intubation but did not control for laryngoscope type (video laryngoscope vs direct laryngoscope), we fit mixed-effects logistic regression models examining the 1) the association between laryngoscope type (video laryngoscope vs direct laryngoscope) and the Cormack-Lehane grade of view and 2) the interaction between grade of view, laryngoscope type (video laryngoscope vs direct laryngoscope), and the incidence of successful intubation on the first attempt., Results: We analyzed 1,786 patients: 467 (26.2%) in the direct laryngoscope group and 1,319 (73.9%) in the video laryngoscope group. The use of a video laryngoscope was associated with an improved grade of view as compared with a direct laryngoscope (adjusted odds ratio for increasingly favorable grade of view 3.14, 95% confidence interval [CI] 2.47 to 3.99). Successful intubation on the first attempt occurred in 83.2% of patients in the video laryngoscope group and 72.2% of patients in the direct laryngoscope group (absolute difference 11.1%, 95% CI 6.5% to 15.6%). Video laryngoscope use modified the association between grade of view and successful intubation on the first attempt such that intubation on the first attempt was similar between video laryngoscope and direct laryngoscope at a grade 1 view and higher for video laryngoscope than direct laryngoscope at grade 2 to 4 views (P<.001 for interaction term)., Conclusions: Among critically ill adults undergoing tracheal intubation, the use of a video laryngoscope was associated both with a better view of the vocal cords and with a higher probability of successfully intubating the trachea when the view of the vocal cords was incomplete in this observational analysis. However, a multicenter, randomized trial directly comparing the effect of a video laryngoscope with a direct laryngoscope on the grade of view, success, and complications is needed., (Copyright © 2023 American College of Emergency Physicians. Published by Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
45. Reducing Central Venous Catheter Use through Adoption of Guidelines for Peripheral Catheter-based Vasopressor Delivery.
- Author
-
Gandotra S, Wunsch H, Bosch NA, Walkey AJ, and Teja B
- Subjects
- Humans, Vasoconstrictor Agents, Central Venous Catheters, Catheterization, Central Venous, Catheterization, Peripheral, Catheter-Related Infections
- Published
- 2023
- Full Text
- View/download PDF
46. Prophylactic Administration of Vasopressors Prior to Emergency Intubation in Critically Ill Patients: A Secondary Analysis of Two Multicenter Clinical Trials.
- Author
-
Fuchita M, Pattee J, Russell DW, Driver BE, Prekker ME, Barnes CR, Brewer JM, Doerschug KC, Gaillard JP, Gandotra S, Ghamande S, Gibbs KW, Hughes CG, Janz DR, Khan A, Mitchell SH, Page DB, Rice TW, Self WH, Smith LM, Stempek SB, Trent SA, Vonderhaar DJ, West JR, Whitson MR, Williamson K, Semler MW, Casey JD, and Ginde AA
- Abstract
Hypotension affects approximately 40% of critically ill patients undergoing emergency intubation and is associated with an increased risk of death. The objective of this study was to examine the association between prophylactic vasopressor administration and the incidence of peri-intubation hypotension and other clinical outcomes., Design: A secondary analysis of two multicenter randomized clinical trials. The clinical effect of prophylactic vasopressor administration was estimated using a one-to-one propensity-matched cohort of patients with and without prophylactic vasopressors., Setting: Seven emergency departments and 17 ICUs across the United States., Patients: One thousand seven hundred ninety-eight critically ill patients who underwent emergency intubation at the study sites between February 1, 2019, and May 24, 2021., Interventions: None., Measurements and Main Results: The primary outcome was peri-intubation hypotension defined as a systolic blood pressure less than 90 mm Hg occurring between induction and 2 minutes after tracheal intubation. A total of 187 patients (10%) received prophylactic vasopressors prior to intubation. Compared with patients who did not receive prophylactic vasopressors, those who did were older, had higher Acute Physiology and Chronic Health Evaluation II scores, were more likely to have a diagnosis of sepsis, had lower pre-induction systolic blood pressures, and were more likely to be on continuous vasopressor infusions prior to intubation. In our propensity-matched cohort, prophylactic vasopressor administration was not associated with reduced risk of peri-intubation hypotension (41% vs 32%; p = 0.08) or change in systolic blood pressure from baseline (-12 vs -11 mm Hg; p = 0.66)., Conclusions: The administration of prophylactic vasopressors was not associated with a lower incidence of peri-intubation hypotension in our propensity-matched analysis. To address potential residual confounding, randomized clinical trials should examine the effect of prophylactic vasopressor administration on peri-intubation outcomes., Competing Interests: Dr. Fuchita received a departmental seed grant from the University of Colorado, Department of Anesthesiology, for biostatistical support. Dr. Casey was supported in part by the National Institutes of Health (NIH) (K23HL153584). Dr. Semler was supported in part by the NIH (K23HL143053). The remaining authors have disclosed that they do not have any potential conflicts of interest., (Copyright © 2023 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of the Society of Critical Care Medicine.)
- Published
- 2023
- Full Text
- View/download PDF
47. Individualized Treatment Effects of Bougie versus Stylet for Tracheal Intubation in Critical Illness.
- Author
-
Seitz KP, Spicer AB, Casey JD, Buell KG, Qian ET, Graham Linck EJ, Driver BE, Self WH, Ginde AA, Trent SA, Gandotra S, Smith LM, Page DB, Vonderhaar DJ, West JR, Joffe AM, Doerschug KC, Hughes CG, Whitson MR, Prekker ME, Rice TW, Sinha P, Semler MW, and Churpek MM
- Subjects
- Adult, Humans, Calibration, Laryngoscopy, Critical Illness therapy, Intubation, Intratracheal adverse effects
- Abstract
Rationale: A recent randomized trial found that using a bougie did not increase the incidence of successful intubation on first attempt in critically ill adults. The average effect of treatment in a trial population, however, may differ from effects for individuals. Objective: We hypothesized that application of a machine learning model to data from a clinical trial could estimate the effect of treatment (bougie vs. stylet) for individual patients based on their baseline characteristics ("individualized treatment effects"). Methods: This was a secondary analysis of the BOUGIE (Bougie or Stylet in Patients Undergoing Intubation Emergently) trial. A causal forest algorithm was used to model differences in outcome probabilities by randomized group assignment (bougie vs. stylet) for each patient in the first half of the trial (training cohort). This model was used to predict individualized treatment effects for each patient in the second half (validation cohort). Measurements and Main Results: Of 1,102 patients in the BOUGIE trial, 558 (50.6%) were the training cohort, and 544 (49.4%) were the validation cohort. In the validation cohort, individualized treatment effects predicted by the model significantly modified the effect of trial group assignment on the primary outcome ( P value for interaction = 0.02; adjusted qini coefficient, 2.46). The most important model variables were difficult airway characteristics, body mass index, and Acute Physiology and Chronic Health Evaluation II score. Conclusions: In this hypothesis-generating secondary analysis of a randomized trial with no average treatment effect and no treatment effect in any prespecified subgroups, a causal forest machine learning algorithm identified patients who appeared to benefit from the use of a bougie over a stylet and from the use of a stylet over a bougie using complex interactions between baseline patient and operator characteristics.
- Published
- 2023
- Full Text
- View/download PDF
48. Black representation in critical care randomized controlled trials: a meta-epidemiological study.
- Author
-
Tchouambou Youmbi C, Gilman TJ, Ndzana Siani IC, Olaye IE, Popoola AF, Yahya SA, Kyeremanteng K, Gandotra S, Casey JD, Semler MW, Mbuagbaw L, Khalifa A, and Rochwerg B
- Subjects
- Adult, Humans, Black People, Canada, United States, Black or African American, Critical Care, Randomized Controlled Trials as Topic, Patient Selection
- Abstract
Purpose: The under-representation of Black people within critical care research limits the generalizability of randomized controlled trials (RCTs). This meta-epidemiologic study investigated the proportionate representation of Black people enrolled at USA and Canadian study sites from high impact critical care RCTs., Source: We searched for critical care RCTs published in general medicine and intensive care unit (ICU) journals between 1 January 2016 and 31 December 2020. We included RCTs that enrolled critically ill adults at USA or Canadian sites and provided race-based demographic data by study site. We compared study-based racial demographics with site-level city-based demographics and pooled representation of Black people across studies, cities, and centres using a random effects model. We used meta-regression to explore the impact of the following variables on Black representation in critical care RCTs: country, drug intervention, consent model, number of centres, funding, study site city, and year of publication., Principal Findings: We included 21 eligible RCTs. Of these, 17 enrolled at only USA sites, two at only Canadian sites, and two at both USA and Canadian sites. Black people were under-represented in critical care RCTs by 6% compared with population-based city demographics (95% confidence interval, 1 to 11). Using meta-regression, after controlling for pertinent variables, the country of the study site was the only significant source of heterogeneity (P = 0.02)., Conclusion: Black people are under-represented in critical care RCTs compared with site-level city-based demographics. Interventions are required to ensure adequate Black representation in critical care RCTs at both USA and Canadian study sites. Further research is needed to investigate the factors contributing to Black under-representation in critical care RCTs., (© 2023. Canadian Anesthesiologists' Society.)
- Published
- 2023
- Full Text
- View/download PDF
49. Effect of P2Y12 Inhibitors on Organ Support-Free Survival in Critically Ill Patients Hospitalized for COVID-19: A Randomized Clinical Trial.
- Author
-
Berger JS, Neal MD, Kornblith LZ, Gong MN, Reynolds HR, Cushman M, Althouse AD, Lawler PR, McVerry BJ, Kim KS, Baumann Kreuziger L, Solomon SD, Kosiborod MN, Berry SM, Bochicchio GV, Contoli M, Farkouh ME, Froess JD, Gandotra S, Greenstein Y, Hade EM, Hanna N, Hudock K, Hyzy RC, Ibáñez Estéllez F, Iovine N, Khanna AK, Khatri P, Kirwan BA, Kutcher ME, Leifer E, Lim G, Lopes RD, Lopez-Sendon JL, Luther JF, Nigro Maia L, Quigley JG, Wahid L, Wilson JG, Zarychanski R, Kindzelski A, Geraci MW, and Hochman JS
- Subjects
- Humans, Male, Middle Aged, Critical Illness therapy, Hemorrhage, Hospital Mortality, Ticagrelor therapeutic use, COVID-19, Purinergic P2Y Receptor Agonists therapeutic use
- Abstract
Importance: Platelet activation is a potential therapeutic target in patients with COVID-19., Objective: To evaluate the effect of P2Y12 inhibition among critically ill patients hospitalized for COVID-19., Design, Setting, and Participants: This international, open-label, adaptive platform, 1:1 randomized clinical trial included critically ill (requiring intensive care-level support) patients hospitalized with COVID-19. Patients were enrolled between February 26, 2021, through June 22, 2022. Enrollment was discontinued on June 22, 2022, by the trial leadership in coordination with the study sponsor given a marked slowing of the enrollment rate of critically ill patients., Intervention: Participants were randomly assigned to receive a P2Y12 inhibitor or no P2Y12 inhibitor (usual care) for 14 days or until hospital discharge, whichever was sooner. Ticagrelor was the preferred P2Y12 inhibitor., Main Outcomes and Measures: The primary outcome was organ support-free days, evaluated on an ordinal scale that combined in-hospital death and, for participants who survived to hospital discharge, the number of days free of cardiovascular or respiratory organ support up to day 21 of the index hospitalization. The primary safety outcome was major bleeding, as defined by the International Society on Thrombosis and Hemostasis., Results: At the time of trial termination, 949 participants (median [IQR] age, 56 [46-65] years; 603 male [63.5%]) had been randomly assigned, 479 to the P2Y12 inhibitor group and 470 to usual care. In the P2Y12 inhibitor group, ticagrelor was used in 372 participants (78.8%) and clopidogrel in 100 participants (21.2%). The estimated adjusted odds ratio (AOR) for the effect of P2Y12 inhibitor on organ support-free days was 1.07 (95% credible interval, 0.85-1.33). The posterior probability of superiority (defined as an OR > 1.0) was 72.9%. Overall, 354 participants (74.5%) in the P2Y12 inhibitor group and 339 participants (72.4%) in the usual care group survived to hospital discharge (median AOR, 1.15; 95% credible interval, 0.84-1.55; posterior probability of superiority, 80.8%). Major bleeding occurred in 13 participants (2.7%) in the P2Y12 inhibitor group and 13 (2.8%) in the usual care group. The estimated mortality rate at 90 days for the P2Y12 inhibitor group was 25.5% and for the usual care group was 27.0% (adjusted hazard ratio, 0.96; 95% CI, 0.76-1.23; P = .77)., Conclusions and Relevance: In this randomized clinical trial of critically ill participants hospitalized for COVID-19, treatment with a P2Y12 inhibitor did not improve the number of days alive and free of cardiovascular or respiratory organ support. The use of the P2Y12 inhibitor did not increase major bleeding compared with usual care. These data do not support routine use of a P2Y12 inhibitor in critically ill patients hospitalized for COVID-19., Trial Registration: ClinicalTrials.gov Identifier: NCT04505774.
- Published
- 2023
- Full Text
- View/download PDF
50. Protocol and statistical analysis plan for the PREOXI trial of preoxygenation with noninvasive ventilation vs oxygen mask.
- Author
-
Gibbs KW, Ginde AA, Prekker ME, Seitz KP, Stempek SB, Taylor C, Gandotra S, White H, Resnick-Ault D, Khan A, Mohmed A, Brainard JC, Fein DG, Aggarwal NR, Whitson MR, Halliday SJ, Gaillard JP, Blinder V, Driver BE, Palakshappa JA, Lloyd BD, Wozniak JM, Exline MC, Russell DW, Ghamande S, Withers C, Hubel KA, Moskowitz A, Bastman J, Andrea L, Sottile PD, Page DB, Long MT, Goranson JK, Malhotra R, Long BJ, Schauer SG, Connor A, Anderson E, Maestas K, Rhoads JP, Womack K, Imhoff B, Janz DR, Trent SA, Self WH, Rice TW, Semler MW, and Casey JD
- Abstract
Background: Hypoxemia is a common and life-threatening complication during emergency tracheal intubation of critically ill adults. The administration of supplemental oxygen prior to the procedure ("preoxygenation") decreases the risk of hypoxemia during intubation., Research Question: Whether preoxygenation with noninvasive ventilation prevents hypoxemia during tracheal intubation of critically ill adults, compared to preoxygenation with oxygen mask, remains uncertain., Study Design and Methods: The PRagmatic trial Examining OXygenation prior to Intubation (PREOXI) is a prospective, multicenter, non-blinded randomized comparative effectiveness trial being conducted in 7 emergency departments and 17 intensive care units across the United States. The trial compares preoxygenation with noninvasive ventilation versus oxygen mask among 1300 critically ill adults undergoing emergency tracheal intubation. Eligible patients are randomized in a 1:1 ratio to receive either noninvasive ventilation or an oxygen mask prior to induction. The primary outcome is the incidence of hypoxemia, defined as a peripheral oxygen saturation <85% between induction and 2 minutes after intubation. The secondary outcome is the lowest oxygen saturation between induction and 2 minutes after intubation. Enrollment began on 10 March 2022 and is expected to conclude in 2023., Interpretation: The PREOXI trial will provide important data on the effectiveness of noninvasive ventilation and oxygen mask preoxygenation for the prevention of hypoxemia during emergency tracheal intubation. Specifying the protocol and statistical analysis plan prior to the conclusion of enrollment increases the rigor, reproducibility, and interpretability of the trial., Clinical Trial Registration Number: NCT05267652., Competing Interests: Conflicts of Interest and Financial Disclosures: Kevin W. Gibbs MD reports financial support and travel were provided by US Department of Defense. Adit. A. Ginde MD MPH reports financial support was provided by US Department of Defense. Matthew E. Prekker MD MPH reports financial support was provided by US Department of Defense. Kevin P. Seitz MD MSc reports financial support was provided by National Heart Lung and Blood Institute. Susan B. Stempek PA MBA reports financial support was provided by American College of Chest Physicians. Akram Khan MD reports financial support was provided by United Therapeutics Corporation. Akram Khan MD reports financial support was provided by 4D Medicine Ltd. Akram Khan MD reports financial support was provided by Regeneron Pharmaceuticals Inc. Akram Khan MD reports financial support was provided by Roche. Akram Khan MD reports financial support was provided by Dompé pharmaceutical. Jessica A. Palakshappa MD MS reports financial support was provided by National Institute on Aging. Joanne M. Wozniak PA MS reports was provided by American College of Chest Physicians. Matthew C. Exline MD, MPH reports financial support was provided by Abbott Laboratories. Derek W. Russell MD reports financial support was provided by National Heart Lung and Blood Institute. Shekar Ghamande MD reports financial support was provided by US Department of Defense. Ari Moskowitz MD MPH reports financial support was provided by National Heart Lung and Blood Institute. Jill Bastman BSN reports financial support was provided by US Department of Defense. Micah T. Long MD reports financial support was provided by pocket cards. Steven G. Schauer DO MS reports was provided by US Department of Defense. David Janz MD MSc reports financial support was provided by US Department of Defense. Matthew W. Semler MD MSc reports financial support was provided by US Department of Defense. Matthew W. Semler MD MSc reports financial support was provided by National Heart Lung and Blood Institute. Jonathan D. Casey MD MSc reports was provided by US Department of Defense. Jonathan D. Casey MD MSc reports was provided by National Heart Lung and Blood Institute. Jonathan D. Casey MD MSc reports travel was provided by Fisher & Paykel Healthcare Inc. Todd W Rice MD MSc reports a relationship with Cumberland Pharmaceuticals Inc that includes: consulting or advisory and equity or stocks. Derek W. Russell MD reports a relationship with Achieve Life Science Inc that includes: equity or stocks. Matthew W. Semler MD MSc reports a relationship with Baxter International Inc that includes: consulting or advisory.
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.